Amy Miles - Regencell Bioscience Chairperson and CEO

RGC Stock  USD 3.47  0.02  0.58%   

CEO

Ms. Amy E. Miles is the Chairman of the Board, Chief Executive Officer of the Company. She has served as Chief Executive Officer since June 2009 and became Chair of the Board of Directors in March 2015. Prior thereto, Ms. Miles served as our Executive Vice President, Chief Financial Officer and Treasurer from March 2002 to June 2009. Additionally, Ms. Miles has served as the Chief Executive Officer of Regal Cinemas, Inc. since June 2009 since 2015.
Age 49
Tenure 9 years
Address Chinachem Leighton Plaza, Causeway Bay, Hong Kong
Phone852 2155 0823
Webhttps://www.regencellbioscience.com
Miles formerly served as the Executive Vice President, Chief Financial Officer and Treasurer of Regal Cinemas, Inc. from January 2000 to June 2009. Prior thereto, Ms. Miles served as Senior Vice President of Finance from April 1999, when she joined Regal Cinemas, Inc. Prior to joining the Company, Ms. Miles was a Senior Manager with Deloitte & Touche LLP from 1998 to 1999. From 1989 to 1998, she was with PricewaterhouseCoopers LLP.

Amy Miles Latest Insider Activity

Tracking and analyzing the buying and selling activities of Amy Miles against Regencell Bioscience stock is an integral part of due diligence when investing in Regencell Bioscience. Amy Miles insider activity provides valuable insight into whether Regencell Bioscience is net buyers or sellers over its current business cycle. Note, Regencell Bioscience insiders must abide by specific rules, including filing SEC forms every time they buy or sell Regencell Bioscience'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.

Regencell Bioscience Management Efficiency

The company has Return on Asset of (0.2559) % which means that on every $100 spent on assets, it lost $0.2559. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.4171) %, meaning that it generated no profit with money invested by stockholders. Regencell Bioscience's management efficiency ratios could be used to measure how well Regencell Bioscience manages its routine affairs as well as how well it operates its assets and liabilities. At present, Regencell Bioscience's Return On Assets are projected to slightly decrease based on the last few years of reporting. At present, Regencell Bioscience's Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Return On Assets is expected to grow to 0.04, whereas Total Assets are forecasted to decline to about 10.8 M.
The company has 463.67 K in debt with debt to equity (D/E) ratio of 0.07, which may show that the company is not taking advantage of profits from borrowing. Regencell Bioscience has a current ratio of 13.66, demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due. Debt can assist Regencell Bioscience until it has trouble settling it off, either with new capital or with free cash flow. So, Regencell Bioscience's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Regencell Bioscience sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Regencell to invest in growth at high rates of return. When we think about Regencell Bioscience's use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 10 records

CEO Age

Maxime PicatUnited Guardian
41
Keith AndersonSkyline
58
Robert FrancesconCentury Communities
66
Mark YostSkyline
52
Shailesh JejurikarProcter Gamble
57
Ma FranciscoProcter Gamble
52
Richard FloreaSkyline
55
Martin RiantProcter Gamble
55
Paul HowesNewpark Resources
64
Fama FranciscoProcter Gamble
50
Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine bioscience company. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong. Regencell Bioscience operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 13 people. Regencell Bioscience Holdings (RGC) is traded on NASDAQ Exchange in USA. It is located in Chinachem Leighton Plaza, Causeway Bay, Hong Kong and employs 12 people. Regencell Bioscience is listed under Biotechnology category by Fama And French industry classification.

Management Performance

Regencell Bioscience Leadership Team

Elected by the shareholders, the Regencell Bioscience's board of directors comprises two types of representatives: Regencell Bioscience inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Regencell. The board's role is to monitor Regencell Bioscience's management team and ensure that shareholders' interests are well served. Regencell Bioscience's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Regencell Bioscience's outside directors are responsible for providing unbiased perspectives on the board's policies.
Jacques Vaillancourt, Executive Chairman of the Board
YiChung Chao, Special Director
YatPui Au, Chief Officer
Antonia Assang, Senior Management
Jeffrey Pontius, Independent Director
John Gray, President Director
Jack Tyrrell, Independent Director
Thomas Bell, Lead Independent Director
Wai Chung, COO Officer
Michelle Chan, Financial Controller
Charles Brymer, Independent Director
Mark Brown, CFO
Kenneth Booth, Director
Sean Keenan, Director
David Ownby, CFO, Principal Accounting Officer, Executive VP and Treasurer
Tien Chau, Executive Officer
Lee Thomas, Independent Director
Michael Campbell, Non-Executive Chairman of the Board
Robert McLeod, Director
Peter Ball, Director
Stephen Kaplan, Independent Director
Peter Brandow, Executive Vice President General Counsel
Douglas Fulcher, Independent Director
Gregory Dunn, Pres and COO
YatGai Au, Chairman Founder
Amy Miles, Chairperson and CEO
David Keyte, Independent Director
Susan Mitchell, Director
Alex Yemenidjian, Independent Director
Tim Mikula, Investor Relations
Peter Bala, President CEO, Director
George Ireland, Director
Michael McInnis, Independent Director

Regencell Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Regencell Bioscience a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Currently Active Assets on Macroaxis

When determining whether Regencell Bioscience offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Regencell Bioscience's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Regencell Bioscience Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Regencell Bioscience Holdings Stock:
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Regencell Bioscience Holdings. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price.
Note that the Regencell Bioscience information on this page should be used as a complementary analysis to other Regencell Bioscience's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.

Complementary Tools for Regencell Stock analysis

When running Regencell Bioscience's price analysis, check to measure Regencell Bioscience's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Regencell Bioscience is operating at the current time. Most of Regencell Bioscience's value examination focuses on studying past and present price action to predict the probability of Regencell Bioscience's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Regencell Bioscience's price. Additionally, you may evaluate how the addition of Regencell Bioscience to your portfolios can decrease your overall portfolio volatility.
Global Correlations
Find global opportunities by holding instruments from different markets
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Is Regencell Bioscience's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Regencell Bioscience. If investors know Regencell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Regencell Bioscience listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.45)
Return On Assets
(0.26)
Return On Equity
(0.42)
The market value of Regencell Bioscience is measured differently than its book value, which is the value of Regencell that is recorded on the company's balance sheet. Investors also form their own opinion of Regencell Bioscience's value that differs from its market value or its book value, called intrinsic value, which is Regencell Bioscience's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Regencell Bioscience's market value can be influenced by many factors that don't directly affect Regencell Bioscience's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Regencell Bioscience's value and its price as these two are different measures arrived at by different means. Investors typically determine if Regencell Bioscience is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Regencell Bioscience's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.